MAML3 inhibitors belong to a specific class of chemical compounds designed to target and interact with the MAML3 protein. MAML3, which stands for Mastermind Like Transcriptional Coactivator 3, is a crucial protein involved in various cellular processes, particularly within the context of gene transcription and signaling pathways. Its primary role lies in acting as a transcriptional coactivator, facilitating the activation of specific genes by binding to various transcription factors, notably those belonging to the Notch signaling pathway. The Notch signaling pathway plays a pivotal role in controlling cell fate determination, differentiation, and development in multicellular organisms. Therefore, MAML3 inhibitors are designed to modulate this pathway by specifically blocking the function of MAML3.
The mechanism of action of MAML3 inhibitors typically involves interfering with the interaction between MAML3 and the transcription factors it coactivates. By disrupting this interaction, these inhibitors effectively impede the activation of target genes downstream of the Notch pathway, thereby influencing various cellular processes. The development and utilization of MAML3 inhibitors are driven by the need to understand and manipulate the Notch signaling pathway for research purposes, as well as to explore potential applications in areas such as cancer biology and developmental biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits tyrosine kinase activity in BCR-ABL, c-KIT, and PDGFR, studied in the research of leukemia. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Blocks the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases, including Raf kinases and VEGFR, to inhibit angiogenesis and tumor growth. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Selective inhibitor of Janus kinases (JAK1 and JAK2) for myeloproliferative disorders. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Inhibits mTOR kinase, blocking cell proliferation and angiogenesis in various cancers. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Blocks the androgen receptor (AR) signaling pathway in prostate cancer. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Selective inhibitor of BCL-2, promoting apoptosis in leukemia and lymphoma cells. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Inhibits MEK1 and MEK2, interfering with the MAPK signaling pathway in cancer. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits Bruton's tyrosine kinase (BTK) for B-cell malignancy. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor, disrupting DNA repair in cancer cells, especially in BRCA-mutated tumors. | ||||||